Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 71Lung Neoplasms 32Triple Negative Breast Neoplasms 23Breast Neoplasms 19Small Cell Lung Carcinoma 15Ovarian Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Endometrial Neoplasms 13Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 10Fallopian Tube Neoplasms 10Neoplasm Metastasis 9Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Carcinoma 5Adenocarcinoma of Lung 5Esophageal Neoplasms 4Uterine Cervical Neoplasms 3Pathologic Complete Response 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mesothelioma 3Melanoma 3Lung Diseases 3Head and Neck Neoplasms 3Esophageal Squamous Cell Carcinoma 3Central Nervous System Neoplasms 3Uterine Neoplasms 2Thoracic Neoplasms 2Sarcoma 2

Interventions

Cisplatin 12Gemcitabine 9Specimen Handling 6Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Drug Therapy 5toripalimab 4Platinum 4Nivolumab 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3Radiotherapy 3Immune Checkpoint Inhibitors 3sintilimab 2Ipilimumab 2Immunoglobulin G 2Docetaxel 2Disulfides 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2tislelizumab 1relatlimab 1pembrolizumab 1olaparib 1fluciclovine F-18 1dehydroftorafur 1cemiplimab 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Carboplatin × 30 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06029270 2026-06-03

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
156 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡